[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":220},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,68,90,114,136,157,177,200],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100638579","phase-2-a-study-of-imm0306-in-igg4-related-disease-100638579",false,"NCT07621939","A Study of IMM0306 in IgG4-Related Disease","A Phase II\u002FIII Clinical Study to Evaluate the Efficacy and Safety of IMM0306 in Participants With IgG4-Related Disease (IgG4-RD)","Inclusion Criteria:\n\n* Clinical diagnosis of IgG4-RD;\n* Meeting 2019 ACR\u002FEULAR classification criteria with an inclusion score ≥20;\n* At least two organs\u002Fsites involved during the disease course;\n* Prior or recent IgG4-RD flare requiring initiation or continuation of GC treatment at informed consent.\n\nExclusion Criteria:\n\n* Fibrotic manifestation as the only clinical manifestation of the current relapse;\n* Significant hematologic or hepatic abnormalities;\n* Recent B-cell-depleting therapy, alkylating agents, DMARDs or immunosuppressants;\n* Other chronic active immune diseases requiring long-term use of immunosuppressants;\n* Active malignancy or active malignancy within 10 years;\n* Significant cardiac disease;\n* Active infection or active TB;\n* Severe pulmonary disease;\n* Recent opportunistic infection;\n* Alcohol\u002Fdrug abuse;\n* Pregnancy, lactation or failure to meet contraception requirements.","ALL","18 Years",{"count":19,"type":20},125,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","The goal of this clinical trial is to learn if IMM0306 works to reduce the risk of disease relapse in participants with IgG4-related disease (IgG4-RD). It will also learn about the safety and tolerability of IMM0306. The main questions it aims to answer are:\n\n* Does IMM0306 reduce the risk of disease relapse in participants with IgG4-RD?\n* What medical problems do participants have when receiving IMM0306?\n* How does IMM0306 behave in the body, and does the body develop anti-drug antibodies against IMM0306? In the Phase II part, all participants will receive IMM0306. In the Phase III part, researchers will compare IMM0306 with placebo to evaluate whether IMM0306 reduces the risk of disease relapse in participants with IgG4-RD.\n\nParticipants will:\n\n* Receive IMM0306 or placebo by intravenous infusion once weekly for 4 consecutive weeks, with the same treatment repeated 6 months later\n* Start a planned glucocorticoid taper from Day 1 and gradually reduce oral prednisone or equivalent until complete discontinuation after 8 weeks\n* Visit the study site for efficacy and safety assessments, including disease relapse assessment, IgG4-RD responder index assessment, laboratory tests, imaging examinations, electrocardiograms, pharmacokinetic sampling, immunogenicity sampling, biomarker sampling, and adverse event assessment.",[27],"IgG4-Related Disease","NOT_YET_RECRUITING","2026-06-01",{"date":31,"type":32},"2026-06-02","ACTUAL",{"date":34,"type":20},"2026-07",{"date":36,"type":20},"2030-05",{"name":38,"class":39},"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100576679","early-phase-1-a-clinical-study-of-imc-001-for-injection-in-improving-atherosclerotic-plaque-stability-in-patients-with-acute-coronary-syndrome-100576679","NCT06788431","A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.","A Two-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Investigator-Initiated Trial (IIT) Evaluating the Safety and Preliminary Efficacy of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.","Inclusion Criteria:\n\n1. Fully comprehend the purpose, characteristics, methodology, and potential adverse reactions of this study; voluntarily participate in the research and sign an informed consent form prior to any related assessments;\n2. Male or female subjects aged ≥18 years and ≤75 years;\n3. Clinically diagnosed with acute coronary syndrome (ACS) (including acute myocardial infarction or unstable angina) and meeting the following criteria:\n\n   ① Patients with ≥30% and \\\u003C70% stenosis in the target vessel as demonstrated by coronary angiography or coronary CTA;\n\n   ② At least one plaque exhibiting detectable low attenuation (coronary CTA -30 HU to 30 HU), with calcified volume constituting \\\u003C50% of total plaque volume;\n\n   ③ High-sensitivity C-reactive protein (hsCRP) ≥ 1.0 mg\u002FL;\n4. Patients must receive guideline-directed standard treatment for coronary artery disease;\n5. Women of childbearing potential or men (unless their partner is infertile) must agree to use medically approved contraception from screening until 6 months after the last dose; Male subjects must not donate sperm, and female subjects must not donate eggs for at least 6 months after signing the informed consent form and until 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Participation in any drug or medical device clinical trial within one month prior to screening.\n2. Previous treatment with coronary artery bypass grafting (CABG), left ventricular assist device (LVAD) implantation, heart transplantation, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or any planned procedure for these treatments during the study period.\n3. New York Heart Association (NYHA) functional class III or IV, or a known recent left ventricular ejection fraction (LVEF) \\\u003C 40% (as determined by left ventricular angiography, radionuclide ventriculography, or echocardiography).\n4. Uncontrolled arrhythmia within 3 months prior to screening, defined as recurrent, symptomatic, and refractory to medical therapy, such as ventricular tachycardia, atrial fibrillation with rapid ventricular rate and paroxysmal supraventricular tachycardia, or a family history of long QT syndrome.\n5. Evidence of active or suspected malignancy within 3 years prior to screening (excluding only carcinoma in situ or basal\u002Fsquamous cell skin cancer treated with curative therapy); life expectancy less than 1 year.\n6. Any major surgery within 3 months prior to screening or planned major surgery during the study period;\n7. Presence or suspected ongoing severe infection within 8 weeks prior to first dosing (defined as requiring hospitalisation or intravenous anti-infective therapy), chronic or recurrent bacterial, fungal, or viral infections requiring medical intervention, including syphilis, human immunodeficiency virus (HIV) infection, active hepatitis B or C infection history;\n8. Presence of severe hepatic dysfunction, defined as: any alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level \\> 3 times the upper limit of normal (ULN) at final screening assessment.\n9. Moderate to severe renal impairment, defined as: estimated glomerular filtration rate (eGFR) \\\u003C 45 mL\u002Fmin\u002F1.73 m²at screening (calculated using the 2021 CKD-EPI formula; see Appendix 4), or serum creatinine \\> 1.5 × ULN.\n10. Presence of any type of autoimmune disease; current or planned systemic anti-inflammatory therapy, such as immunomodulatory agents and chemotherapeutic agents.\n11. Individuals who have donated blood or experienced blood loss\n\n    ≥400 mL within 3 months prior to dosing, have a history of severe spontaneous bleeding, or have received blood transfusions or blood products. Abnormal laboratory parameters within 7 days without transfusion, including but not limited to: white blood cell count below the lower limit of normal, neutrophil count \\\u003C1.5×109\u002FL, haemoglobin \\\u003C100 g\u002FL, platelet count ≤100×109 \u002FL, total bilirubin \\>1.5×ULN, International Normalised Ratio (INR) \\>2×ULN, or activated partial thromboplastin time (APTT) \\>2×ULN.\n12. Known prior allergy to macromolecular protein preparations\u002Fmonoclonal antibodies, known allergy to the investigational medicinal product or its excipients or similar drugs, prior treatment with IMC-001.\n13. Existence of contraindications for CCTA examination and history of iodine contrast agent allergy, etc.\n14. Screening CCTA reveals moderate to severe calcification (coronary artery calcium score \\[Agatston score\\] ≥ 300) or tortuosity in target vessels, judged by the investigator to compromise study assessment.\n15. Receipt of any type of vaccination within one month prior to screening, or planned vaccination during the study treatment period.\n16. History of substance abuse (including illicit drug use) and\u002For alcohol abuse within 6 months prior to screening; subjects with alcohol abuse defined as consuming 14 units of alcohol weekly: 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine.\n17. Pregnant or lactating women; those with a positive pregnancy test during the screening period.\n18. Any other disease or condition deemed by the investigator to make the subject unsuitable for participation in this study, in addition to those listed above.","75 Years",{"count":49,"type":20},18,[51],"EARLY_PHASE1","A two-center, randomized, double-blind, placebo-controlled, dose-escalation IIT clinical study evaluating the safety and preliminary efficacy of injectable IMC-001 in improving atherosclerotic plaque stability in patients with acute coronary syndrome. The plan is to conduct 2 dose groups, with 9 subjects enrolled in each group, including 6 in the treatment group and 3 in the control group. The treatment group will receive IMC-001 along with optimal drug therapy, with a total of 12 subjects included, while the control group will receive a placebo along with optimal drug therapy, with a total of 6 subjects included.",[54],"Atherosclerosis",[56,57],"Acute coronary syndrome","atherosclerosis","RECRUITING","2026-04-12",{"date":61,"type":32},"2026-04-15",{"date":63,"type":32},"2025-03-10",{"date":65,"type":20},"2026-10-30",{"name":38,"class":39},2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100620258","phase-3-imm0306-in-combination-with-lenalidomide-vs-placebo-in-combination-with-lenalidomide-in-patients-with-relapsedrefractory-follicular-lymphoma-100620258","NCT07355283","IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed\u002FRefractory Follicular Lymphoma","A Randomized, Double-Blind, Controlled, Multicenter, Phase III Clinical Study of IMM0306 (Amulirafusp Alfa) for Injection in Combination With Lenalidomide Versus Placebo in Combination With Lenalidomide in Patients With Relapsed\u002FRefractory Follicular Lymphoma","Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n2. At least one measurable lesion (as per Lugano 2014 criteria).\n3. Histologically confirmed CD20-positive Follicular Lymphoma, Grade 1, 2, or 3a.\n4. Previously received at least two prior systemic regimens, including at least one line containing an anti-CD20 monoclonal antibody.\n5. Adequate hepatic, hematologic, and renal function.\n6. Expected survival at least 6 months.\n\nExclusion Criteria:\n\n1. Autologous HSCT within 100 days prior to first administration, or any prior allogeneic HSCT or solid organ transplantation.\n2. History of central nervous system (CNS) metastases or active CNS involvement.\n3. History of other malignancy within the past 5 years.\n4. Severe organic cardiovascular or cerebrovascular diseases.\n5. History of severe allergic reactions to any components of the trial drug, any macromolecular protein preparations or monoclonal antibodies.\n6. Previous treatment with anti-CD47 monoclonal antibody\u002FSIRPα fusion protein.\n7. Human immunodeficiency virus (HIV) infection.\n8. Echocardiography examination indicating left ventricular ejection fraction (LVEF) \\\u003C 55%.\n9. Active infection requiring systemic therapy (e.g., fungal, bacterial, viral).",{"count":76,"type":20},198,[24],"This study is a randomized, controlled, double-blind, multicenter, phase III clinical study to evaluate the efficacy of IMM0306 (Amulirafusp Alfa)in combination with lenalidomide versus placebo in combination with lenalidomide in patients with Relapsed\u002FRefractory Follicular lymphoma. Primary endpoints are Complete Remission Rate (CRR) and Progression-Free Survival (PFS).",[80],"Relapsed\u002FRefractory Follicular Lymphoma","2026-01-25",{"date":83,"type":32},"2026-01-27",{"date":85,"type":20},"2026-02",{"date":87,"type":20},"2030-10",{"name":38,"class":39},1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":97,"minAge":98,"maxAge":47,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":89},"100602021","phase-1-a-randomized-double-blind-placebo-controlled-single-and-multiple-dose-escalation-phase-i-clinical-trial-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-imc-003-for-injection-in-healthy-postmenopausal-women-100602021","NCT07118085","A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women","Inclusion Criteria:\n\n* (1) The age range for screening is 45 to 75 years (inclusive of the boundary values), and post-menopausal females; (2) Before screening, spontaneous amenorrhea has lasted for at least 12 months, or spontaneous amenorrhea for at least 6 months or amenorrhea caused by hysterectomy with serum FSH level \\> 40 IU\u002FL, or bilateral oophorectomy with or without hysterectomy for ≥ 6 weeks; (3) At the time of screening, the weight is ≥ 45 kg and the body mass index (BMI) is within the range of 18.0 to 30.0 kg\u002Fm2 (inclusive of the boundary values); (4) Physical examination, vital sign examination, electrocardiogram examination, laboratory tests, etc. are normal (platelet count is greater than the lower limit of the normal value) or judged by the investigator to be abnormal but without clinical significance; (5) Fully understand the trial content, the trial drug, the trial process, etc., can communicate well with the researcher, willing to abide by the trial regulations, and voluntarily participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* The subjects must meet any of the following conditions to be eligible for this trial:\n\n  (1) (During the screening period\u002FIn the admission interview) They had or currently have clinically significant diseases or abnormalities as determined by the investigators, including but not limited to cardiovascular, respiratory, digestive tract, endocrine, hematological, liver, immune, metabolic, urinary, skin, central nervous system, and chronic kidney diseases, or diseases that the investigators consider to have safety issues or affect the PK evaluation; (2) (During the screening period\u002FIn the admission interview) They have active bleeding (such as peptic ulcer, intracranial hemorrhage, skin ecchymosis, nosebleed, gum bleeding) at present; or within the previous 6 months, they have any disease history that may increase the risk of bleeding (such as tumor bleeding, spontaneous hematoma, eye bleeding, hemoptysis, gastrointestinal bleeding or ulcer, hematuria, frequent nosebleeds\u002Fgum bleeding, frequent subcutaneous or skin ecchymosis, etc.); (3) (During the screening period\u002FIn the admission interview) They have a history of malignant tumors in the past or currently; (4) (During the screening period\u002FIn the admission interview) They have a history of thrombosis, cerebral infarction, or myocardial infarction; (5) (During the screening period\u002FIn the admission interview) They cannot tolerate venipuncture blood collection or have a history of fainting or hemoversion; (6) (During the screening period\u002FIn the admission interview) They have a history of tuberculosis, or they have a severe local or systemic infection within 3 months before screening; (7) (During the screening period\u002FIn the admission interview) They have a severe allergic history (such as angioedema, anaphylactic shock), allergic constitution (such as being allergic to pollen, two or more drugs\u002Ffood), or are known to have previously been allergic to large molecule protein preparations\u002Fmonoclonal antibodies, known to be allergic to the test drug or its excipients or similar drugs; (8) (During the screening period\u002FIn the admission interview) They have used any prescription drugs or herbal medicines within 4 weeks before administration, and used over-the-counter drugs or dietary supplements (including vitamins, calcium supplements, etc.) within 2 weeks; (9) (During the screening period\u002FIn the admission interview) They have used drugs that may affect bone metabolism within 6 months before administration, and are expected to use drugs that may affect bone metabolism during this trial. These drugs include but are not limited to the following: estrogen-containing contraceptives, bisphosphonates, fluoride, hormone replacement therapy (such as terbutalone, estrogen, estrogen-like compounds, such as raloxifene), calcitonin, strontium, parathyroid hormone or its derivatives, vitamin D supplements (\\>1000 IU\u002Fday), calcium supplements, glucocorticoids (except those who used inhaled or other local corticosteroid drugs within 2 weeks before screening), anabolic steroid drugs (such as megestrolone, phenylpropionate nandrolone, hydroxyethyl testosterone, stanazolol, kalicornol, danazol, etc.), calcitriol, etc.; and any drugs that affect platelet function or cause changes in the body's coagulation function; (10) (During the screening period\u002FIn the admission interview) They have used teriparatide; (11) (During the screening period\u002FIn the admission interview) They have used any drugs that affect platelet count, function, or cause changes in the body's coagulation function within 4 weeks before administration; (12) (During the screening period\u002FIn the admission interview) They have donated blood or had a blood loss of ≥ 400 mL within 3 months before administration; (13) (During the screening period\u002FIn the admission interview) They have undergone major surgery within 3 months before screening or are expected to have major surgery during this trial (including the screening period); (14) (During the screening period\u002FIn the admission interview) They are heavy smokers or have a daily smoking amount of ≥ 5 cigarettes within 3 months before administration, or they cannot stop using any tobacco products during the trial; (15) (Screening period \u002F Admission consultation) Alcoholics or those who consumed more than 14 standard units of alcohol per week within 6 months prior to the first administration (1 standard unit contains 17.5 ml or 14 grams of pure alcohol, the alcohol content of different types of beverages is indicated by volume ratio, and the daily alcohol intake is equivalent to 70 ml of 50° liquor or 700 ml of 5° beer), or those who were unwilling to stop drinking alcohol or consuming any alcoholic products during the trial; those with a positive alcohol breath test result; (16) (Screening period \u002F Admission consultation) Those who consumed excessive tea, coffee, and\u002For caffeinated beverages every day within 3 months prior to screening (more than 8 cups, 1 cup = 250 mL); (17) (Screening period \u002F Admission consultation) Those with a history of drug abuse, or those with positive results from multiple drug screening tests for urine combined screening; (18) (Screening period \u002F Admission consultation) Those who have previously used drugs targeting the same target, including participants in clinical studies of drugs targeting the same target; (19) (Screening period \u002F Admission consultation) Those who participated in any clinical trials of drugs or medical devices within 3 months prior to administration and used the study drugs, vaccines, or devices; (20) Those with positive results for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or Treponema pallidum specific antibody; (21) (Screening period \u002F Admission consultation) Those cannot guarantee that they will refrain from consuming drugs, foods, or beverages that can induce or inhibit liver metabolic enzymes from 1 week before the trial and throughout the trial period; (22) Other reasons as determined by the investigator that make participation in this trial inappropriate.",true,"FEMALE","45 Years",{"count":100,"type":20},56,[102],"PHASE1","this study is a randomized, double-blind, placebo-controlled, single and multiple dose escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IMC-003 for injection in healthy postmenopausal women.",[105],"Healthy Postmenopausal Women","2025-12-07",{"date":108,"type":32},"2025-12-15",{"date":110,"type":32},"2025-08-18",{"date":112,"type":20},"2027-08-20",{"name":38,"class":39},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100565875","phase-3-imm01azacitidine-vs-placebo-azacitidine-in-patients-with-newly-diagnosed-chronic-myelomonocytic-leukemia-cmml1-2-100565875","NCT06647862","IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)","A Randomized, Controlled, Double-Blind, Multicenter, Phase Ⅲ Study to Evaluate the Efficacy and Safety of IMM01 (Timdarpacept) in Combination With Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)","Inclusion Criteria:\n\n* Age ≥ 18 years old, regardless of gender;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n* Life expectancy ≥ 12 weeks;\n* Patients with CMML diagnosed according to WHO 2016 criteria, including CMML-1 and CMML-2;\n* White blood cell count ≤ 13×10⁹\u002FL before the first treatment with the study drug (hydroxyurea and leukapheresis are allowed).\n* Patients must be treatment-naïve to any systemic agents for CMML (e.g., azacitidine, decitabine,chemotherapy\\\u003C1 cycle, and the washout period should be more than 28 days, which is acceptable.), allogeneic stem cell transplant for CMML. Note: During screening and study participation, subjects may continue oral corticosteroids for diseases other than CMML (e.g. asthma) at a stable daily dose equivalent to ≤ 10 mg prednisone. In addition, supportive care in the form of blood transfusions or growth factors is not considered prior therapy in this case and is permitted prior to and as needed during the study.\n\nExclusion Criteria:\n\n* Previous treatment with anti-CD47 monoclonal antibody\u002FSIRPα fusion protein;\n* History of allogeneic stem cell transplant and other organ transplants; Patients who have undergone autologous haematopoietic stem cell transplant;\n* Prior diagnosis of: therapy-related Myelodysplastic syndrome \u002F Myeloproliferative neoplasm(MDS\u002FMPN); MDS evolved from a pre-existing Myelodysplastic syndrome \u002F Myeloproliferative neoplasm (MDS\u002FMPN) ;other MDS\u002FMPN including atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS\u002FMPN. Patients positive for BCR-ABL fusion genes, PDGFRA, PDGFRB, and FGFR1 rearrangements need to be excluded;\n* Current or history of central nervous system (CNS) leukemia, extramedullary leukemia(excluding: Enlarged spleen, enlarged liver, enlarged lymph nodes), or myeloid sarcoma;\n* Diagnosis of other malignant neoplasms within 3 years prior to the first dose. Exceptions: a. Radically treated cervical carcinoma in situ or non-melanoma skin cancer,Surgery-cured prostate cancer and papillary thyroid cancer; b. a second primary cancer that has been curatively treated and has no recurrence within three years;",{"count":122,"type":20},170,[24],"This study is a randomized, controlled, double-blind, multicenter, phase Ⅲ clinical study to evaluate the efficacy of IMM01(timdarpacept) in combination with azacitidine versus placebo in combination with azacitidine in patients with newly diagnosed chronic leukemia monocytic (CMML1-2).Primary endpoint are Complete remission rate and Overall survival.",[126],"Chronic Myelomonocytic Leukemia","2025-11-23",{"date":129,"type":32},"2025-11-25",{"date":131,"type":32},"2024-11-11",{"date":133,"type":20},"2029-10-24",{"name":38,"class":39},43,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":89},"100606072","phase-1-a-study-of-imm2510--imm01-combination-therapy-in-patients-with-advanced-solid-tumors-100606072","NCT07170787","A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors","Phase Ib\u002FII Clinical Study of IMM2510 for Injection Combined With IMM01 for Injection in Advanced Solid Tumors","Inclusion Criteria:\n\n* Participant has provided informed consent prior to initiation of any study specific activities\u002Fprocedures.\n* Age greater than or equal to 18 years old at the same time of signing the informed consent.\n* Histologically or cytologically confirmed for Solid Tumor.\n* Eastern Cooperative Oncology Group (ECOG) 0 to 1.\n* Adequate organ function as defined in protocol.\n\nExclusion Criteria:\n\n* History of other malignancy within the past 5 years with exceptions.\n* Systemic chemotherapy was administered within 3 weeks prior to the first administration.\n* Activated symptomatic brain metastases and leptomeningeal disease.\n* History of inflammatory bowel disease.\n* Participants with symptoms and\u002For clinical signs and\u002For uncontrolled active systemic infection within 14 days prior to the first dose of study treatment.\n\nParticipant has known active infection requiring parenteral antibiotic treatment.",{"count":144,"type":20},104,[102,23],"This is a Phase 1, open-label, dose-escalation and cohort expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant protein) combine with IMM01(Anti-CD47 Recombinant Protein) in patients with advanced solid tumors who have received at least first line treatment in past.",[148],"Advanced Solid Tumors","2025-09-11",{"date":151,"type":32},"2025-09-12",{"date":153,"type":20},"2025-10-15",{"date":155,"type":20},"2029-07",{"name":38,"class":39},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":176,"locationsCount":89},"100574865","phase-1-a-study-of-imm2510--imm27m-combination-therapy-in-patients-with-advanced-solid-tumors-100574865","NCT06764836","A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors","An Open-Label, Multi-Centre, Single-Arm, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Efficacy of IMM2510 in Combination With IMM27M in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. The patient can understand the procedures and methods of this clinical trial. After giving full informed consent, the patient voluntarily participates in it and signs the informed consent form.\n2. Aged between 18 and 75 years old (including both ends), regardless of gender.\n3. Clinical diagnosis:\n\n   Dose escalation phase: Patients with advanced malignant solid tumors confirmed by histology or cytology, who have failed previous standard treatments, have no standard treatment regimens or are not suitable for standard treatment at present, including but not limited to hepatocellular carcinoma, triple-negative breast cancer, soft tissue sarcoma, non-small cell lung cancer, epithelial ovarian cancer, small cell lung cancer, malignant melanoma, colorectal cancer, ovarian cancer, endometrial cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, etc.\n\n   Dose expansion phase: The following tumor types are included: a. Patients with advanced hepatocellular carcinoma who have failed or could not tolerate at least one line of previous systemic treatment; b. Patients with locally advanced, unresectable or metastatic triple-negative breast cancer confirmed by histology or cytology, who have failed or could not tolerate at least one line of previous systemic treatment; c. Patients with other advanced malignant solid tumors (except those with triple-negative breast cancer and advanced hepatocellular carcinoma) confirmed by histology or cytology, who have failed or could not tolerate at least one line of previous systemic treatment, including but not limited to soft tissue sarcoma, non-small cell lung cancer, epithelial ovarian cancer, small cell lung cancer, malignant melanoma, colorectal cancer, ovarian cancer, endometrial cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, etc.\n4. Dose escalation phase: According to RECIST version 1.1, there should be at least one evaluable tumor lesion; Dose expansion phase: According to RECIST version 1.1, there should be at least one measurable tumor lesion.\n5. ECOG performance status score of 0 - 1.\n6. The expected survival time is more than 3 months.\n7. There should be sufficient organ function. Hematological system (without receiving blood transfusion or hematopoietic stimulating factor treatment within 14 days): Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL, Platelet count (PLT) ≥ 100 × 10⁹\u002FL, Hemoglobin (Hb) ≥ 90 g\u002FL. For patients with HCC accompanied by liver cirrhosis, ANC ≥ 1.0 × 10⁹\u002FL and platelet count ≥ 90 × 10⁹\u002FL are acceptable for enrollment.\n\n   Liver function: Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN), for patients with liver metastasis or liver cancer, TBIL ≤ 3.0 × ULN; Alanine aminotransferase (ALT) ≤ 2.5 × ULN, for patients with liver metastasis or liver cancer, ALT ≤ 5.0 × ULN; Aspartate aminotransferase (AST) ≤ 2.5 × ULN, for patients with liver metastasis or liver cancer, AST ≤ 5.0 × ULN.\n\n   Renal function: Creatinine clearance rate (Ccr) ≥ 50 ml\u002Fmin (calculated according to the Cockcroft-Gault formula), Urinary protein \\\u003C 2+ or 24-hour urinary protein quantification \\\u003C 1.0 g.\n\n   Coagulation function: Prothrombin time (PT) ≤ 1.5 × ULN, Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN, International normalized ratio (INR) ≤ 1.5 × ULN.\n\n   Cardiac function: 12-lead electrocardiogram, QTc interval ≤ 480 ms, Echocardiogram, Left ventricular ejection fraction (LVEF) ≥ 50%.\n\n   Thyroid function: Thyroid-stimulating hormone (TSH) ≤ 1 × ULN (if abnormal, FT3 and FT4 levels should be observed simultaneously. If FT3 and FT4 levels are normal, enrollment is allowed).\n\n   Liver function grading for HCC patients: Child-Pugh score ≤ 7 points.\n8. Qualified patients (both male and female) with fertility must agree to use reliable contraceptive methods (hormonal or barrier methods or abstinence) together with their partners during the trial period and at least 6 months after the last administration.\n9. The patient must be informed of this study before the trial and voluntarily sign the written informed consent form.\n\nExclusion Criteria:\n\nPatients meeting any one of the following criteria will be excluded from this study:\n\n1. Previous treatment history:\n\n   1. Patients who received mitomycin and nitrosourea chemotherapy within 6 weeks before the first administration.\n   2. Patients who received the last systemic anti-tumor treatment, including chemotherapy, radiotherapy, immunotherapy, biological agents or endocrine therapy, etc., within 4 weeks before the first administration.\n   3. Patients who received hormonal anti-tumor treatment or small molecule targeted therapy within 2 weeks before the first administration.\n   4. Patients who received local treatment such as radiotherapy for target lesions within 4 weeks before the first administration, and those who received palliative local treatment for non-target lesions within 2 weeks before the first administration.\n   5. Patients who received non-specific immunomodulatory treatment (such as interleukin, interferon, thymosin, tumor necrosis factor, etc., excluding IL-11 used for treating thrombocytopenia) within 2 weeks before the first administration.\n   6. Patients who previously received the experimental drugs IMM2510 and\u002For IMM27M; those who could not tolerate treatment with anti-CTLA-4 or PD-1\u002FL1 inhibitors (due to toxic and side effects); those who previously used drugs targeting three targets, namely anti-PD-1\u002FL1, VEGF, and CTLA-4 simultaneously in the same regimen.\n   7. Patients who received traditional Chinese medicine with anti-tumor indications within 1 week before the first administration.\n   8. Patients who participated in other clinical trials within 4 weeks before the first administration.\n2. Those with a known severe allergic history to any component of the experimental drug, or those with a history of severe allergic reactions to chimeric or humanized antibodies or fusion proteins.\n3. Those who had any immune-related adverse events (irAE) of grade ≥ 3 in CTCAE V5.0 or that led to the termination of immunotherapy during previous treatment with any immunotherapy drugs.\n4. Those diagnosed with other malignant tumors within 5 years before enrollment. Exceptions: 1) Cervical carcinoma in situ and non-melanoma skin cancer that have been cured; 2) Patients who have been radically cured, unless the patients have been in complete remission for at least 2 years before enrollment and do not require other treatments or will not require other treatments during the study period.\n5. Those with an active second primary cancer that is known and has had no recurrence within 5 years. Exceptions: 1) The investigator believes that both primary cancers can benefit from this study; 2) The investigator has clearly excluded which primary tumor the metastatic lesions belong to.\n6. Patients with primary central nervous system (CNS) malignant tumors or those with active CNS metastases that failed local treatment (radiotherapy or surgical treatment). However, the following patients are allowed to enroll: a. Patients with asymptomatic brain metastases; b. Patients with clinically stable symptoms (i.e., no radiological progression was seen within 4 weeks before the first administration, and any neurological symptoms have returned to the baseline level), and who have not required corticosteroid hormones and other treatments for brain metastases for ≥ 4 weeks.\n7. Patients with hypertension that cannot be controlled by drugs (systolic blood pressure remains \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg after standard treatment), or with pulmonary hypertension or unstable angina pectoris; those who had a myocardial infarction or underwent bypass or stent surgery within 6 months before administration; those with a history of chronic heart failure of grade 3 - 4 according to the New York Heart Association (NYHA) criteria; those with clinically significant valvular diseases; those with severe arrhythmias requiring treatment (except atrial fibrillation and paroxysmal supraventricular tachycardia), including QTcF ≥ 450 ms for men and ≥ 470 ms for women (calculated by the Fridericia formula); those with cerebrovascular accidents (CVA) or transient ischemic attacks (TIA), etc., within 12 months before enrollment.\n8. Those with a history of arterial thrombosis, deep vein thrombosis or pulmonary embolism within 3 months before administration.\n9. Those with a history of moderate or severe dyspnea at rest due to advanced malignant tumors or their complications or severe primary lung diseases, or those currently requiring continuous oxygen inhalation treatment, or those with a history of interstitial lung disease (ILD) or pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc.\n10. Those with diseases that may cause gastrointestinal bleeding or perforation (such as duodenal ulcer, intestinal obstruction, acute Crohn's disease, ulcerative colitis, extensive resection of the stomach and small intestine, etc.); patients with chronic Crohn's disease and ulcerative colitis (except those who have undergone total colectomy and rectal resection) should be excluded even during the inactive period; those with hereditary non-polyposis colorectal cancer or familial adenomatous polyposis syndrome; those with a history of intestinal perforation or intestinal fistula that have not been cured after surgical treatment; esophageal and gastric varices; or the presence of cancer thrombus in the main portal vein; those requiring repeated drainage due to uncontrollable thoracic, abdominal or pericardial effusion that requires puncture and drainage treatment or those with obvious symptoms.\n11. Those with evidence of severe active infections that cannot be controlled (such as sepsis, bacteremia, viremia, etc.).\n12. Those with active tuberculosis infection.\n13. Those with active hepatitis B (HBsAg positive, and HBV DNA higher than the lower limit of detection, and excluding hepatitis caused by drugs or other reasons), or those with active hepatitis C (anti-HCV antibody positive, and HCV RNA higher than the lower limit of detection).\n14. Those with a history of immunodeficiency, including human immunodeficiency virus (HIV) infection, or other immunodeficiency diseases, or those with a history of organ transplantation or hematopoietic stem cell transplantation.\n15. Those with a history of active autoimmune diseases, including but not limited to systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel diseases, Hashimoto's thyroiditis, autoimmune thyroid diseases, multiple sclerosis, etc. Exceptions:\n\n    1. Hypothyroidism that can be controlled only by hormone replacement therapy.\n    2. Skin diseases that do not require systemic treatment (such as vitiligo, psoriasis).\n    3. Controlled celiac disease.\n16. Those who are currently using immunosuppressants or systemic hormone therapy (prednisone at a dose of ≥ 10 mg\u002Fday or other equivalent hormones) and are still using them within 2 weeks before enrollment.\n17. Those who underwent major surgery within 4 weeks before the first administration and have not fully recovered, or those who plan to undergo major surgery within the first 12 weeks after receiving the study drug; those who received minor surgical operations 2 days before enrollment.\n18. Those with incompletely healed skin wounds, surgical sites, trauma sites, severe mucosal ulcers or fractures, and whom the investigator judges to be at risk of bleeding if participating in this study.\n19. Those who received anti-tumor vaccines or live vaccines within 4 weeks before the first administration, or those who plan to receive anti-tumor vaccines or live vaccines during the study period.\n20. Those with a clear history of neurological or mental disorders in the past, such as epilepsy, dementia, and with poor compliance.\n21. Patients with a history of alcoholism or drug abuse within the past year, or with a history of fainting during acupuncture or blood drawing, or those who cannot tolerate venipuncture for blood collection.\n22. Women who are pregnant or breastfeeding; those who do not agree to take sufficient contraceptive measures together with their partners during the study period and within 6 months after the end of receiving the experimental drug.\n23. The investigator believes that there are other reasons why the patient is not suitable to participate in this trial.",{"count":165,"type":20},108,[102],"This study is an open-label, multi-centre, single-arm, phase I clinical study, to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510 (an anti-PD-L1\u002FVEGF bispecific antibody fusion protein) + IMM27M (a humanized Fc-engineered anti-CTLA-4 antibody) combination therapy in patients with advanced solid tumors.",[148,169],"HCC","2025-01-02",{"date":172,"type":32},"2025-01-08",{"date":174,"type":32},"2024-07-23",{"date":83,"type":20},{"name":38,"class":39},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":190,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":4},"100573483","phase-2-a-phase-ii-clinical-study-to-evaluate-the-safety-pharmacokinetic-profile-and-preliminary-efficacy-of-imm2510-in-combination-with-chemotherapy-as-first-line-treatment-in-subjects-with-non-small-cell-lung-cancer-or-triple-negative-breast-cancer-100573483","NCT06746870","A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer","Inclusion Criteria:\n\n1. Fully understand and voluntarily sign the ICF for this study ;\n2. Aged ≥ 18 years old;\n3. Cohort 1: NSCLC; EGFR wild-type and negative for ALK or ROS1 fusion genes. Cohort 1a: Non-squamous NSCLC (NSQ-NSCLC); Cohort 1b: Squamous NSCLC (SQ-NSCLC); Cohort 2: Breast cancer, negative for ER, PR, and HER-2. Definition of negative for ER and PR: IHC ER \\\u003C 1%, IHC PR \\\u003C 1%. Definition of negative for HER-2: IHC HER-2 (-) or (1+); for HER-2 (2+), FISH testing must be performed and the result must be negative;\n4. Cohort 1: Previous systemic treatment for advanced NSCLC has not been received. If neoadjuvant and\u002For adjuvant treatment was previously received, the time from the completion of neoadjuvant and\u002For adjuvant treatment to the occurrence of recurrence\u002Fmetastasis must be ≥ 12 months; Patients enrolled in the safety run-in period have previously failed at least first-line systemic treatment, are intolerant to, or not suitable for first-line systemic treatment for NSCLC; Cohort 2: Previous systemic treatment for advanced TNBC has not been received. If neoadjuvant and\u002For adjuvant treatment included taxane-based anti-tumor treatment, the time from the completion of taxane-based neoadjuvant and\u002For adjuvant treatment to the occurrence of recurrence\u002Fmetastasis must be ≥ 12 months; Patients enrolled in the safety run-in period have previously failed at least first-line systemic treatment, are intolerant to, or not suitable for first-line systemic treatment for TNBC;\n5. ECOG score of 0 or 1;\n6. Have measurable lesions (according to RECIST 1.1).\n7. Expected survival ≥ 12 weeks;\n8. Provide archival tumor tissue samples or newly obtained needle biopsy or surgical resection samples of tumor lesions (previously unirradiated) for central PD-L1 and other biomarker tests. Formalin-fixed, paraffin-embedded (FFPE) tissue blocks are preferred over slides. Newly obtained biopsy samples are preferred over archival samples. Formalin-fixed samples are preferred after the subject is diagnosed with metastatic disease. If a recent biopsy is not feasible, biopsy samples obtained prior to adjuvant\u002Fneoadjuvant chemotherapy are acceptable.\n9. Upon signing the ICF, females of childbearing potential and males must agree to practice effective contraception during the study and for 6 months after the last dose, and females of childbearing potential must have a negative result for pregnancy test within 3 days pre-dose;\n\nExclusion Criteria:\n\n1. Received approved or investigational anti-tumor treatments within 4 weeks prior to the start of study treatment\n2. Received nonspecific immunomodulatory treatments within 2 weeks prior to the start of study treatment;\n3. Previously received any antibody or inhibitor targeting PD-1\u002FPD-L1 or VEGF;\n4. Laboratory abnormalities\n5. History of pulmonary fibrosis or current presence of severe pulmonary functional impairment\n6. Uncontrolled chronic disease\n7. Unresolved toxicity\n8. Uncontrolled brain metastases\n9. Active infection\n10. Bleeding Risk",{"count":184,"type":20},148,[23],"This is a single-arm, multicenter, open-label Phase II clinical study evaluating the efficacy and safety of IMM2510 in combination with chemotherapy as first-line treatment in patients with stage IV metastatic or recurrent NSCLC or unresectable locally advanced or metastatic TNBC.\n\nThe target population includes: Cohort 1: Patients with histologically or cytologically confirmed stage IV metastatic or recurrent NSCLC who are EGFR wild-type and negative for ALK or ROS1 fusion genes, and who have not received prior systemic treatment for NSCLC; Cohort 2: Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic TNBC who are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2), and who have not received prior systemic treatment for TNBC; This study is divided into two phases. Phase I is the safety run-in period, which will preliminarily explore the safety and PK profile of IMM2510 in combination with chemotherapy in patients with NSCLC or TNBC who have previously failed at least first-line systemic treatment, are intolerant to, or not suitable for first-line systemic treatment, to determine the dose for the combination treatment. Phase II is the expanded enrollment period, which will enroll NSCLC patients (Cohort 1; where Cohort 1a is for NSQ-NSCLC and Cohort 1b is for SQ-NSCLC), or TNBC patients (Cohort 2), according to the dose for the combination treatment determined in Phase I, to further explore the preliminary clinical efficacy, safety, and PK profile of IMM2510 in combination with chemotherapy as first-line treatment in patients with NSCLC or TNBC.",[188,189],"NSCLC","TNBC",[188,189,191],"IMM2510","2024-12-18",{"date":194,"type":32},"2024-12-24",{"date":196,"type":20},"2024-12",{"date":198,"type":20},"2026-12",{"name":38,"class":39},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":219,"locationsCount":4},"100551850","phase-3-a-study-of-imm01-plus-tiselizumab-versus-physicians-choice-chemotherapy-in-pdl1-refractory-classical-hodgkin-lymphoma-100551850","NCT06465446","A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma","A Phase III Randomized, Open-label, Multicenter Clinical Study of IMM01 (Timdarpacept) in Combiniation With Tiselizumab Versus Physician's Choice Chemotherapy in PD-(L)1-refractory Classical Hodgkin Lymphoma","Inclusion Criteria:\n\n* Has histologically confirmed diagnosis of classical Hodgkin lymphoma (cHL).\n* PD (L)-1 refractory cHL and exhausted all available treatment options with known clinical benefit.\n* Has adequate bone marrow reserves and organ functions.\n\nExclusion Criteria:\n\n* History of central nervous system (CNS) metastases or active CNS involvement.\n* Received prior systemic anticancer therapy within 4 weeks before randomization.\n* Received prior ani-CD47 or SIRPa treatment.\n* History of human immunodeficiency virus (HIV).\n* Has an active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy.\n* History of severve allergic reactions to any components of trail durg, humanized antibodies or fusion proteins.",{"count":208,"type":20},202,[24],"The purpose of this study is to compare efficacy of IMM01 plus Tiselizumab with physician's choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of IMM01 plus Tiselizumab. The primary study hypotheses are that IMM01 plus Tiselizuma is superior to physician's choice chemotherapy with respect to progression-free survival (PFS) and overall survival (OS).",[212],"Classic Hodgkin Lymphoma","2024-06-19",{"date":215,"type":32},"2024-06-24",{"date":217,"type":20},"2024-06",{"date":155,"type":20},{"name":38,"class":39},""]